Beyond Semaglutide: 6 Next-Generation Metabolic Peptide Drugs Advancing Through the FDA Pipeline in 2026

The next generation GLP-1 drugs advancing through the FDA pipeline in 2026 represent the most significant shift in metabolic medicine in a decade. Six candidates are now in late-stage development, each built on mechanisms that go beyond what semaglutide (Wegovy, Ozempic) can do alone. If you're currently on a GLP-1 therapy — or researching your options — here is what's coming, what the data show, and why it matters to you.

Semaglutide changed obesity treatment. But the science didn't stop there. Dual agonists, triple agonists, amylin combinations, monthly injectables, and restriction-free oral pills are all moving through clinical trials right now. Some have already reached FDA approval. Others are weeks or months away from a decision.

This is where metabolic pharmacology stands today.

Why the Next Generation of GLP-1 Drugs Matters for Patients

Single-receptor GLP-1 agonists like semaglutide are effective, but they have biological ceilings. Most patients on Wegovy reach a plateau at 12–17% body weight reduction. Insulin resistance, appetite dysregulation, and metabolic adaptation work through multiple pathways simultaneously. A drug that activates only one receptor can only interrupt one of those pathways.

The new generation targets two, three, or entirely novel receptor combinations. The result: greater weight loss, improved cardiometabolic markers, and in some cases, potential for weight maintenance even after stopping treatment. Researchers are also addressing the delivery problem — monthly injectables and no-restriction oral pills are now real clinical realities.

For patients managing obesity, insulin resistance, metabolic syndrome, or dyslipidemia, these drugs represent a fundamentally expanded toolkit. Here is what is in it.

The 6 Next-Generation Metabolic Peptide Drugs in the 2026 FDA Pipeline

1. Amycretin (Zenagamtide / NN9487) — Novo Nordisk

What it is: A first-in-class, unimolecular GLP-1 and amylin receptor dual agonist, available in both once-weekly subcutaneous and once-daily oral formulations.

Where it is now: Phase 3 (initiated Q1 2026) for obesity and overweight. Phase 3 for type 2 diabetes announced November 2025. [1,2]

The data:

Amycretin works by combining two complementary satiety systems. The GLP-1 arm slows gastric emptying and reduces appetite via gut-brain signaling. The amylin arm — mimicking a peptide co-secreted alongside insulin from pancreatic beta cells — suppresses glucagon secretion and amplifies satiety signals through hindbrain pathways. [2]

The result is additive, not just parallel. At 24.3% mean weight loss in 36 weeks, the subcutaneous form matches or exceeds what tirzepatide (Zepbound) achieves — and the oral form is already outperforming what most injectable-class drugs produced a decade ago at 12 weeks.

What to watch: Both formulations — subcutaneous and oral — are advancing directly into Phase 3, following positive feedback from regulatory authorities. Phase 3 results for obesity are unlikely before 2027, but the Phase 2 diabetes data already positions amycretin as a potential best-in-class across two major indications. [3]

2. CagriSema (Cagrilintide + Semaglutide 2.4 mg) — Novo Nordisk

What it is: The first fixed-dose injectable combination of a long-acting amylin analogue (cagrilintide 2.4 mg) and a GLP-1 receptor agonist (semaglutide 2.4 mg), administered once weekly.

Where it is now: NDA submitted to the FDA in December 2025. FDA review expected in 2026. [4,5]

The data:

In REDEFINE 1, 91.9% of CagriSema participants achieved at least 5% body weight reduction, compared to 31.5% in the placebo group. [6] The drug outperformed Wegovy (semaglutide 2.4 mg alone) on both weight and glycemic endpoints across multiple trials.

CagriSema is designed around pharmacological synergy. Cagrilintide (amylin analog) and semaglutide target distinct but complementary appetite pathways — the result is weight loss that exceeds what either component produces alone.

What to watch: If approved, CagriSema would be the first injectable amylin-GLP-1 combination on the US market — a new drug class. The FDA review is active in 2026. A US launch is most likely in early 2027. [5]

The amycretin peptide and cagrisema Novo Nordisk programs are both advancing concurrently, making Novo Nordisk's pipeline arguably the most aggressive in the category right now.

3. Orforglipron (Foundayo) — Eli Lilly ✅ FDA APPROVED April 1, 2026

What it is: The first non-peptide, small-molecule oral GLP-1 receptor agonist. It can be taken once daily at any time of day, without food or water restrictions.

Where it is now: FDA approved as Foundayo™ on April 1, 2026, for adults with obesity or overweight with at least one weight-related comorbidity. [7]

The data:

• Average weight loss at the highest dose (17.2 mg): 12.4% over 72 weeks [8]
• Outperformed oral semaglutide (Rybelsus) in head-to-head Phase 3 ACHIEVE-3 trial (The Lancet, Feb 2026), with superior A1C reduction and greater weight loss [9]
• Self-pay pricing: from $149/month for the lowest dose; as low as $25/month with commercial insurance [7]

The orforglipron story matters not for its raw weight loss numbers — which are lower than injectable GLP-1s — but for what it eliminates. Wegovy pill (oral semaglutide) requires a 30-minute fast with specific water volume. Foundayo requires nothing. Take it at 6 AM with coffee or at midnight. Same effect.

This is not a second-best option. For patients who cannot tolerate injections, have compliance challenges with fasting requirements, or are earlier in their metabolic health journey, Foundayo is a genuine first-line tool. It is also the first oral GLP-1 to beat oral semaglutide in a head-to-head randomized trial. [9]

What to watch: Lilly is pursuing FDA approval of Foundayo for type 2 diabetes in 2026. Global submissions are underway. Diabetes approval would dramatically expand prescribing reach.

4. Retatrutide — Eli Lilly

What it is: The world's first GIP, GLP-1, and glucagon triple hormone receptor agonist — a single weekly injection that activates three metabolic pathways simultaneously.

Where it is now: Phase 3. TRIUMPH-1 topline obesity results released May 21, 2026. Multiple additional Phase 3 trials ongoing. [10,11]

The data:

In TRIUMPH-1, 65.3% of participants on retatrutide 12 mg achieved a BMI below 30 — meaning two-thirds of trial participants no longer met the clinical definition of obesity at 80 weeks. [11] The drug also reduced knee osteoarthritis pain by up to 73.1% and sleep apnea severity by up to 60.6%, signaling potential multi-indication impact that goes far beyond the scale.

How does adding glucagon to the mix help? GLP-1 reduces appetite and slows gastric emptying. GIP enhances insulin secretion. Glucagon raises energy expenditure and accelerates fat oxidation directly at the cellular level. Together, the three signals produce metabolic effects that no single- or dual-agonist drug has matched in clinical trial populations. [10]

What to watch: Lilly is expected to file an NDA for retatrutide in obesity in late 2026 or early 2027. This is the next benchmark drug for the category. FDA approval would likely make it the most efficacious obesity pharmacotherapy ever marketed.

5. Survodutide (BI 456906) — Boehringer Ingelheim / Zealand Pharma

What it is: A once-weekly dual glucagon/GLP-1 receptor agonist. Unlike tirzepatide (GLP-1/GIP), survodutide pairs GLP-1 with glucagon — specifically targeting liver fat alongside body weight.

Where it is now: Phase 3 for obesity (SYNCHRONIZE program) and MASH/MASLD (LIVERAGE program). FDA Breakthrough Therapy Designation for non-cirrhotic MASH. Phase 3 results from SYNCHRONIZE-1 presented at ADA 2026 Scientific Sessions. [12,13]

The data:

Survodutide's differentiation is organ-level specificity. The glucagon receptor component drives direct liver fat reduction — something GLP-1 alone achieves indirectly through weight loss. This makes survodutide particularly relevant for patients with fatty liver disease (MASLD/MASH), a condition tightly linked to metabolic syndrome and insulin resistance. [13]

The FDA and EMA have both granted accelerated access programs for survodutide in MASH — Breakthrough Therapy Designation in the US and PRIME scheme in the EU — signaling regulatory agreement that the unmet need here is significant. [12]

What to watch: SYNCHRONIZE-2 (obesity + T2D) results expected in 2026. LIVERAGE data for MASH will likely determine whether survodutide receives a dedicated liver disease approval, a distinct clinical positioning from obesity-focused competitors. NDA filing anticipated in 2026–2027.

6. MariTide (Maridebart Cafraglutide / AMG 133) — Amgen

What it is: A once-monthly (or less frequent) injectable bispecific antibody-peptide conjugate that simultaneously activates GLP-1 receptors and blocks GIP receptors — the inverse of tirzepatide's GIP agonism approach.

Where it is now: Phase 3 (MARITIME program), initiated 2025. Includes chronic weight management, T2D, heart failure, and obstructive sleep apnea trials. [14,15]

The Data:

MariTide works on a structural principle unique in the class. An anti-GIPR monoclonal antibody (IgG2 framework) is site-specifically conjugated to two GLP-1 analogue agonist peptides. The antibody arm blocks GIP signaling; the peptide arms activate GLP-1. [16]

The mechanism is not just different — it is deliberately different. Amgen's genetics research (via deCODE Genetics) identified GIP receptor inhibition, rather than activation, as a weight-loss signal. Evidence from preclinical models showed that simultaneously activating GLP-1 and blocking GIP produced stronger fat loss than targeting either pathway alone. [15]

The half-life of approximately 21 days — three times longer than the longest approved weekly obesity drugs — is what enables monthly dosing. For patients managing a complex medication schedule, or those who find weekly injections burdensome, once-monthly administration is a meaningful quality-of-life improvement. [16]

Amgen has also launched MARITIME-Switch, a Phase 3 study enrolling patients already on weekly GLP-1 treatment to evaluate switching to once-monthly MariTide. This positions MariTide not just as a new patient option, but as a potential step-up for existing GLP-1 users who want less frequent injections. [15]

What to watch: Phase 3 MARITIME results are expected in 2026–2027. MariTide is not the highest weight-loss number in the pipeline, but it may be the most durability-focused — with early signals suggesting weight maintenance even after stopping treatment.

How These 6 Drugs Compare

What This Means for You as a Patient

If you are currently on semaglutide and feeling plateaued, the data above tell you something important. Your plateau is not personal failure. It is pharmacology. A drug targeting one receptor can only do so much against a metabolic system that has adapted.

The new generation of drugs targets the problem differently. CagriSema and amycretin add amylin to the equation. Retatrutide recruits three separate receptor systems. Survodutide goes after liver fat directly. MariTide offers a monthly option that may sustain results after stopping.

The right drug for you depends on your specific metabolic profile — your insulin resistance level, liver health, body composition goals, and how you respond to your current therapy. That is not a question this article can answer. It is a question a Meto clinician can.

Conclusion

The next generation GLP-1 drugs advancing through the FDA pipeline in 2026 are not incremental. They are mechanistically distinct — recruiting new receptor systems, new delivery formats, and new indications that extend far beyond weight management. One is already approved (Foundayo). One has an active FDA review (CagriSema). Three have positive Phase 3 data (retatrutide, survodutide, MariTide). And amycretin is building toward what may be the highest-efficacy obesity drug ever trialed.

This field is moving faster than any individual can track alone. That is why clinical guidance matters. A metabolic clinician who follows this pipeline can help you understand not just what's available today, but how to position your current treatment plan for what's coming next.

Work with a Meto clinician who tracks every development in metabolic medicine →

Frequently Asked Questions

What are the next generation GLP-1 drugs coming in 2026?

The leading next generation GLP-1 drugs advancing in 2026 include amycretin, CagriSema, orforglipron (already FDA-approved as Foundayo), retatrutide, survodutide, and MariTide. Each uses a distinct mechanism — dual agonism, triple agonism, amylin combinations, or GIPR antagonism — to target weight loss and metabolic health beyond what single-receptor GLP-1 drugs like semaglutide achieve.

Is orforglipron (Foundayo) already FDA approved?

Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions. It is available through LillyDirect and retail pharmacies, with commercial insurance copays as low as $25/month.

How does CagriSema compare to Wegovy (semaglutide 2.4 mg)?

CagriSema outperformed semaglutide alone in both obesity and type 2 diabetes trials. In the REDEFINE 1 Phase 3 trial, CagriSema produced a mean weight loss of 22.7% at 68 weeks, compared to roughly 15–17% historically seen with Wegovy. In the REIMAGINE 2 trial in people with type 2 diabetes, CagriSema demonstrated superior HbA1c reduction and greater weight loss than semaglutide at the same dose.

What is retatrutide and why is it generating so much attention?

Retatrutide is Eli Lilly's triple agonist — it activates three hormone receptors (GLP-1, GIP, and glucagon) in a single weekly injection. In Phase 3 TRIUMPH-1 data released May 2026, participants on the 12 mg dose lost an average of 28.3% body weight at 80 weeks, with 65.3% achieving a BMI below 30. Those numbers represent the highest weight loss ever recorded in a late-stage obesity drug trial, surpassing both tirzepatide and semaglutide.

Is MariTide really a once-monthly injection?

Yes. MariTide (maridebart cafraglutide) has a half-life of approximately 21 days — roughly three times longer than weekly obesity injectables — which enables monthly or less frequent dosing. Amgen's Phase 3 MARITIME-Switch trial is specifically enrolling patients already on weekly GLP-1 therapy to evaluate the clinical and practical benefits of switching to once-monthly treatment.

What is amycretin and how is it different from other amylin drugs?

Amycretin (Zenagamtide) is a single molecule that activates both GLP-1 and amylin receptors simultaneously, a design called unimolecular dual agonism. Unlike combination therapies that mix two separate drugs (such as CagriSema), amycretin encodes both mechanisms in one compound, which may improve pharmacokinetic consistency and simplify dosing. Both injectable and oral forms are now in Phase 3 development.

This article is for educational purposes only. It does not constitute medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.